516 related articles for article (PubMed ID: 27591677)
1. The angiogenic switch leads to a metabolic shift in human glioblastoma.
Talasila KM; Røsland GV; Hagland HR; Eskilsson E; Flønes IH; Fritah S; Azuaje F; Atai N; Harter PN; Mittelbronn M; Andersen M; Joseph JV; Hossain JA; Vallar L; Noorden CJ; Niclou SP; Thorsen F; Tronstad KJ; Tzoulis C; Bjerkvig R; Miletic H
Neuro Oncol; 2017 Mar; 19(3):383-393. PubMed ID: 27591677
[TBL] [Abstract][Full Text] [Related]
2. Annexin A2-STAT3-Oncostatin M receptor axis drives phenotypic and mesenchymal changes in glioblastoma.
Matsumoto Y; Ichikawa T; Kurozumi K; Otani Y; Fujimura A; Fujii K; Tomita Y; Hattori Y; Uneda A; Tsuboi N; Kaneda K; Makino K; Date I
Acta Neuropathol Commun; 2020 Apr; 8(1):42. PubMed ID: 32248843
[TBL] [Abstract][Full Text] [Related]
3. Clonal ZEB1-Driven Mesenchymal Transition Promotes Targetable Oncologic Antiangiogenic Therapy Resistance.
Chandra A; Jahangiri A; Chen W; Nguyen AT; Yagnik G; Pereira MP; Jain S; Garcia JH; Shah SS; Wadhwa H; Joshi RS; Weiss J; Wolf KJ; Lin JG; Müller S; Rick JW; Diaz AA; Gilbert LA; Kumar S; Aghi MK
Cancer Res; 2020 Apr; 80(7):1498-1511. PubMed ID: 32041837
[TBL] [Abstract][Full Text] [Related]
4. Molecular heterogeneity in a patient-derived glioblastoma xenoline is regulated by different cancer stem cell populations.
Garner JM; Ellison DW; Finkelstein D; Ganguly D; Du Z; Sims M; Yang CH; Interiano RB; Davidoff AM; Pfeffer LM
PLoS One; 2015; 10(5):e0125838. PubMed ID: 25955030
[TBL] [Abstract][Full Text] [Related]
5. Targeted Proteomics to Assess the Response to Anti-Angiogenic Treatment in Human Glioblastoma (GBM).
Demeure K; Fack F; Duriez E; Tiemann K; Bernard A; Golebiewska A; Bougnaud S; Bjerkvig R; Domon B; Niclou SP
Mol Cell Proteomics; 2016 Feb; 15(2):481-92. PubMed ID: 26243272
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia upregulates HIG2 expression and contributes to bevacizumab resistance in glioblastoma.
Mao XG; Wang C; Liu DY; Zhang X; Wang L; Yan M; Zhang W; Zhu J; Li ZC; Mi C; Tian JY; Hou GD; Miao SY; Song ZX; Li JC; Xue XY
Oncotarget; 2016 Jul; 7(30):47808-47820. PubMed ID: 27329597
[TBL] [Abstract][Full Text] [Related]
7. Loss of endothelial programmed cell death 10 activates glioblastoma cells and promotes tumor growth.
Zhu Y; Zhao K; Prinz A; Keyvani K; Lambertz N; Kreitschmann-Andermahr I; Lei T; Sure U
Neuro Oncol; 2016 Apr; 18(4):538-48. PubMed ID: 26254477
[TBL] [Abstract][Full Text] [Related]
8. The gain-of-function GLI1 transcription factor TGLI1 enhances expression of VEGF-C and TEM7 to promote glioblastoma angiogenesis.
Carpenter RL; Paw I; Zhu H; Sirkisoon S; Xing F; Watabe K; Debinski W; Lo HW
Oncotarget; 2015 Sep; 6(26):22653-65. PubMed ID: 26093087
[TBL] [Abstract][Full Text] [Related]
9. EGFRvIII/integrin β3 interaction in hypoxic and vitronectinenriching microenvironment promote GBM progression and metastasis.
Liu Z; Han L; Dong Y; Tan Y; Li Y; Zhao M; Xie H; Ju H; Wang H; Zhao Y; Zheng Q; Wang Q; Su J; Fang C; Fu S; Jiang T; Liu J; Li X; Kang C; Ren H
Oncotarget; 2016 Jan; 7(4):4680-94. PubMed ID: 26717039
[TBL] [Abstract][Full Text] [Related]
10. Angiopoietin-4 promotes glioblastoma progression by enhancing tumor cell viability and angiogenesis.
Brunckhorst MK; Wang H; Lu R; Yu Q
Cancer Res; 2010 Sep; 70(18):7283-93. PubMed ID: 20823154
[TBL] [Abstract][Full Text] [Related]
11. Loss of cytoskeleton protein ADD3 promotes tumor growth and angiogenesis in glioblastoma multiforme.
Kiang KM; Zhang P; Li N; Zhu Z; Jin L; Leung GK
Cancer Lett; 2020 Apr; 474():118-126. PubMed ID: 31958485
[TBL] [Abstract][Full Text] [Related]
12. Up-regulation of macrophage migration inhibitory factor gene and protein expression in glial tumor cells during hypoxic and hypoglycemic stress indicates a critical role for angiogenesis in glioblastoma multiforme.
Bacher M; Schrader J; Thompson N; Kuschela K; Gemsa D; Waeber G; Schlegel J
Am J Pathol; 2003 Jan; 162(1):11-7. PubMed ID: 12507885
[TBL] [Abstract][Full Text] [Related]
13. EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation.
Eskilsson E; Rosland GV; Talasila KM; Knappskog S; Keunen O; Sottoriva A; Foerster S; Solecki G; Taxt T; Jirik R; Fritah S; Harter PN; Välk K; Al Hossain J; Joseph JV; Jahedi R; Saed HS; Piccirillo SG; Spiteri I; Leiss L; Euskirchen P; Graziani G; Daubon T; Lund-Johansen M; Enger PØ; Winkler F; Ritter CA; Niclou SP; Watts C; Bjerkvig R; Miletic H
Neuro Oncol; 2016 Dec; 18(12):1644-1655. PubMed ID: 27286795
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive analysis of glycolytic enzymes as therapeutic targets in the treatment of glioblastoma.
Sanzey M; Abdul Rahim SA; Oudin A; Dirkse A; Kaoma T; Vallar L; Herold-Mende C; Bjerkvig R; Golebiewska A; Niclou SP
PLoS One; 2015; 10(5):e0123544. PubMed ID: 25932951
[TBL] [Abstract][Full Text] [Related]
15. Tumor microenvironment tenascin-C promotes glioblastoma invasion and negatively regulates tumor proliferation.
Xia S; Lal B; Tung B; Wang S; Goodwin CR; Laterra J
Neuro Oncol; 2016 Apr; 18(4):507-17. PubMed ID: 26320116
[TBL] [Abstract][Full Text] [Related]
16. Angiogenesis and hypoxia in glioblastoma: a focus on cancer stem cells.
Mongiardi MP
CNS Neurol Disord Drug Targets; 2012 Nov; 11(7):878-83. PubMed ID: 23131159
[TBL] [Abstract][Full Text] [Related]
17. Livin contributes to tumor hypoxia-induced resistance to cytotoxic therapies in glioblastoma multiforme.
Hsieh CH; Lin YJ; Wu CP; Lee HT; Shyu WC; Wang CC
Clin Cancer Res; 2015 Jan; 21(2):460-70. PubMed ID: 25370472
[TBL] [Abstract][Full Text] [Related]
18. The Anti-Warburg Effect Elicited by the cAMP-PGC1α Pathway Drives Differentiation of Glioblastoma Cells into Astrocytes.
Xing F; Luan Y; Cai J; Wu S; Mai J; Gu J; Zhang H; Li K; Lin Y; Xiao X; Liang J; Li Y; Chen W; Tan Y; Sheng L; Lu B; Lu W; Gao M; Qiu P; Su X; Yin W; Hu J; Chen Z; Sai K; Wang J; Chen F; Chen Y; Zhu S; Liu D; Cheng S; Xie Z; Zhu W; Yan G
Cell Rep; 2017 Jan; 18(2):468-481. PubMed ID: 28076790
[TBL] [Abstract][Full Text] [Related]
19. High-capacity glycolytic and mitochondrial oxidative metabolisms mediate the growth ability of glioblastoma.
Kim J; Han J; Jang Y; Kim SJ; Lee MJ; Ryu MJ; Kweon GR; Heo JY
Int J Oncol; 2015 Sep; 47(3):1009-16. PubMed ID: 26202438
[TBL] [Abstract][Full Text] [Related]
20. Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy.
Castro BA; Flanigan P; Jahangiri A; Hoffman D; Chen W; Kuang R; De Lay M; Yagnik G; Wagner JR; Mascharak S; Sidorov M; Shrivastav S; Kohanbash G; Okada H; Aghi MK
Oncogene; 2017 Jun; 36(26):3749-3759. PubMed ID: 28218903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]